Key Financial’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$902 Sell
50
-1,000
-95% -$18.7K ﹤0.01% 1185
2026
Q2
$18.9K Buy
1,050
+1,000
+2,000% +$18.9K ﹤0.01% 738
2026
Q1
$1.08K Hold
50
– – ﹤0.01% 1246
2025
Q4
$1.06K Hold
50
– – ﹤0.01% 1248
2025
Q3
$956 Hold
50
– – ﹤0.01% 1276
2025
Q2
$846 Hold
50
– – ﹤0.01% 1288
2025
Q1
$3.16K Hold
50
– – ﹤0.01% 1087
2024
Q4
$6.02K Hold
50
– – ﹤0.01% 934
2024
Q3
$6.18K Hold
50
– – ﹤0.01% 923
2024
Q2
$7.82K Hold
50
– – ﹤0.01% 838
2024
Q1
$6.41K Hold
50
– – ﹤0.01% 874
2023
Q4
$4.77K Hold
50
– – ﹤0.01% 947
2023
Q3
$6K Hold
50
– – ﹤0.01% 848
2023
Q2
$5.67K Hold
50
– – ﹤0.01% 888
2023
Q1
$6.82K Hold
50
– – ﹤0.01% 758
2022
Q4
$5.47K Hold
50
– – ﹤0.01% 775
2022
Q3
$5K Hold
50
– – ﹤0.01% 806
2022
Q2
$4K Hold
50
– – ﹤0.01% 855
2022
Q1
$4K Hold
50
– – ﹤0.01% 840
2021
Q4
$4K Hold
50
– – ﹤0.01% 755
2021
Q3
$5K Buy
50
+8
+19% +$616 ﹤0.01% 712
2021
Q2
$3K Hold
42
– – ﹤0.01% 748
2021
Q1
$3K Hold
42
– – ﹤0.01% 662
2020
Q4
$7K Buy
+42
New +$6.22K 0.01% 512
2020
Q2
– Sell
-42
Closed -$4K – 550
2020
Q1
$4K Buy
+42
New +$4.8K ﹤0.01% 536

Other funds holding SRPT

Key Financial's SRPT Position: Q3 2026 in Review

Key Financial reduced its Sarepta Therapeutics (SRPT) stake by 95% in Q3 2026, selling an estimated $18.7K and leaving 50 shares worth $902. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

Key Financial first reported a position in SRPT in Q1 2020 and has held it in 25 quarters since. The position peaked at $18.9K in Q2 2026. 228 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Key Financial held 50 shares of Sarepta Therapeutics worth $902 as of Q3 2026.
  • Key Financial sold 1,000 Sarepta Therapeutics shares in Q3 2026, an estimated $18.7K.
  • Sarepta Therapeutics made up ﹤0.01% of Key Financial's portfolio in Q3 2026, its #1185 holding.
  • Key Financial first reported a position in Sarepta Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Key Financial's Sarepta Therapeutics position peaked at $18.9K in Q2 2026.
  • 228 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.